Nanotheranostics for personalized medicine.

Nanotheranostics for personalized medicine.
复制标题

DOI:
10.1586/erm.13.15
复制
发表时间:
2013-04
影响因子:
5.1
通讯作者:
Chen X
Chen X
中科院分区:
医学3区
文献类型:
--
作者:
Kim TH;Lee S;Chen X

文献摘要

参考文献

被引文献

相似文献

纳米肿瘤学是利用纳米技术的好处将诊断和治疗功能集成在一个系统中的技术,对个性化医疗极具吸引力。因为治疗癌症不是一刀切的方案,它需要治疗适应病人的特定生物分子。个性化和精准医疗(PM)就是这样做的。它识别生物标记物以获得对诊断的理解,进而根据精确的诊断治疗特定的疾病。通过主要利用纳米颗粒的独特性质来实现生物标志物的识别和药物传递,纳米肿瘤学可以应用于无创发现和靶向成像生物标志物,并根据生物标志物的分布进一步提供治疗。这是治疗学必须扮演的一个重要而充满希望的角色。然而,正如本专家意见所述,目前为PM应用设计的基于纳米技术的治疗系统还不够。PM是一个不断发展的领域,将成为未来生物医学,特别是癌症治疗学发现的驱动力。在这篇文章中,作者剖析了成功的基于纳米肿瘤学的PM的需求。
Nanotheranostics, the integration of diagnostic and therapeutic function in one system using the benefits of nanotechnology, is extremely attractive for personalized medicine. Because treating cancer is not a one-size-fits-all scenario, it requires therapy to be adapted to the patient’s specific biomolecules. Personalized and precision medicine (PM) does just that. It identifies biomarkers to gain an understanding of the diagnosis and in turn treating the specific disorder based on the precise diagnosis. By predominantly utilizing the unique properties of nanoparticles to achieve biomarker identification and drug delivery, nanotheranostics can be applied to noninvasively discover and target image biomarkers and further deliver treatment based on the biomarker distribution. This is a large and hopeful role theranostics must fill. However, as described in this expert opinion, current nanotechnology-based theranostics systems engineered for PM applications are not yet sufficient. PM is an ever-growing field that will be a driving force for future discoveries in biomedicine, especially cancer theranostics. In this article, the authors dissect the requirements for successful nanotheranostics-based PM.
DOI: 10.7150/thno.4068
发表时间: 2012
期刊: Theranostics
影响因子: 12.4
作者:
Choi KY;Swierczewska M;Lee S;Chen X
通讯作者: Chen X
DOI: 10.1126/science.286.5439.531
发表时间: 1999-10-15
期刊: SCIENCE
影响因子: 56.9
作者:
Golub, TR;Slonim, DK;Lander, ES
通讯作者: Lander, ES
使用一步标记的整合素靶向示踪剂 18F-AlF-NOTA-PRGD2 对心肌梗塞/再灌注后的血管生成进行 PET 成像。
DOI: 10.1007/s00259-011-2052-1
发表时间: 2012-04
影响因子: 9.1
作者:
Gao, Haokao;Lang, Lixin;Guo, Ning;Cao, Feng;Quan, Qimeng;Hu, Shuo;Kiesewetter, Dale O.;Niu, Gang;Chen, Xiaoyuan
通讯作者: Chen, Xiaoyuan
DOI: 10.7150/thno/v01p0048
发表时间: 2011-01-17
期刊: Theranostics
影响因子: 12.4
作者:
Beer AJ;Kessler H;Wester HJ;Schwaiger M
通讯作者: Schwaiger M
DOI: 10.1038/35000501
发表时间: 2000-02-03
期刊: NATURE
影响因子: 64.8
作者:
Alizadeh, AA;Eisen, MB;Staudt, LM
通讯作者: Staudt, LM